In this free webinar, learn an overview of tools to assist in developing clonal cell lines and their relative pros and cons. Attendees will gain a better understanding of the underlying theory and science behind limiting dilution and potential pitfalls to avoid. The featured speakers will discuss their real-world experiences of providing evidence of clonality to the medicines regulator.
TORONTO, Aug. 30, 2022 /PRNewswire-PRWeb/ -- For a monoclonal antibody-based therapeutic an important aspect of an investigational new drug (IND) application, is demonstrating that the production cell line is clonally derived. In this webinar, the featured speakers will explore single cell cloning and its associated techniques.
There are several technologies/techniques that can be used to demonstrate clonal derivation. One prominent technique that has been used for many years, is the limiting dilution (LD). This is a common method of achieving clonally derived cells within the cell line development (CLD) process. In some cases, two rounds of LD are performed without the support of whole well imaging, or a single round is performed coupled with whole well imaging. CLD labs may be using a combination of LD for some projects and an automated single cell printer for others.
Regardless of how LD is implemented, it's important to understand the theory, science and statistics behind it. More recently, automated single cell seeding, and high-quality imaging technologies have come to the fore, both as alternatives and as complementary tools to LD.
In this webinar, industry experts give their perspective on the following: How to interpret the data — for example, seeding at 0.5 cells per well doesn't mean that 50 percent of resulting wells will be clonally derived; How best to mitigate risks associated with LD — for example, the possibility of selecting a cell line that is not clonally derived; And questions on clonality from the medicines regulator in an IND review.
As the industry shifts away from LD, the speakers discuss the latest alternative technologies, namely automated single cell seeding and whole well imaging together with their practical, economic and commercial benefits.
Join this webinar to learn about single cell cloning, techniques to achieve clonal derivation and the industry thinking on clonality.
Join John Gill, Sr. Director of Cell Line Development, Gilead Sciences; Arna Andrews PhD, Principal Consultant, Arna Andrews Consulting; and Paul Butler, Senior Product Leader, Advanced Instruments, LLC., for the live webinar on Wednesday, September 21, 2022, at 9am EDT (2pm BST/UK).
For more information, or to register for this event, visit Single Cell Cloning — What Could Possibly go Wrong? AKA Latest Industry Thinking on Clonality.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article